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Background
Acetylcholinestarase inhibitors (AChEIs) are the treat-
ment of choice for mild to moderate Alzheimer’s disease
(AD). Switches between AChEIs are usually performed
when the current therapy is not effective or poorly
tolerated.
Aim
To evaluate the effect of Galantamine treatment in cog-
nition, behavioral symptoms and daily functioning of
patients with mild-to-moderate AD.
Methods
6-month, non-interventional, prospective study. Treat-
ment-naïve patients or those who had failed on a pre-
vious AChEI therapy were enrolled. Naïve patients
started treatment on 8 mg daily. Patients switched from
other AChEIs started at galantamine therapeutic levels
-16 mg- or 24 mg if switched from max dose of rivastig-
mine. Efficacy was assessed using Mini Mental State
Examination (MMSE), Neuropsychiatric Inventory
(NPI), Disability Assessment for Dementia (DAD), and
Cornell Scale. Caregivers also rated patient’s condition
using Clinical Global Impression (CGI) scale. Adverse
events were closely monitored
Results
333 patients were enrolled (58.6% female). The mean
age was 73.5 (SD 6.7) and mean time since diagnosis
was 64.2 months (SD 59.1). At the end of the study, the
mean galantamine dose was 22.4 mg/day (SD 3.2).
95,2% of patients (317/333) had received another AChEI
and inadequate response was the most frequent reason
for switching (70.7%).
Efficacy results on all scales had a statistically signifi-
cant improvement from baseline to month 6. MMSE
was increased: 18.7 (SD 4.2) to 19.9 (SD 4.6), p < 0.001;
and DAD also increased:68.9 (21.0) to 73.7 (16.2),
p = 0.004. NPI, Cornell & CGI were decreased: NPI
12.6 (15.5) to 9.9 (13.2), p < 0.001; Cornell 7.0 (7.7) to
4.6 (5.5), p = 0.003; CGI-Caregivers 3.8 (1.1) to 3.6 (1.2),
p < 0.001.
9,9% of patients had at least one adverse event. Most
were mild involving nausea (23.3%), vomiting (18.3%)
and diarrhea (6.7%). 8 SAEs were recorded.
Conclusions
Discontinuation of a previous AChEI with subsequent
treatment with galantamine at a therapeutic dose level
may improve all clinical aspects of AD. The safety pro-
file recorded in everyday clinical practice was similar to
that reported in double-blind, controlled trials of
galantamine.
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